Alert

NEXGEL Inc. (NXGL)

NasdaqCM: NXGL · Real-Time Price · USD

0.33

-0.06 (-15.38%)

At close: Aug 21, 2026, 3:58 PM

0.34

+2.33%

After-hours: 7:59 PM

The price, the headline numbers and the latest news, in one place.

-15.38% (1D)

Bid	0.41
Market Cap	3.22M
Revenue (ttm)	12.07M
Net Income (ttm)	-6.19M
	n/a
	-0.63
	n/a
	0.83
P/B (ttm)	0.70
P/S (ttm)	0.27
Earnings Date	Nov 10, 2026

Ask	0.42
Volume	338,074
Avg. Volume (20D)	349,732
Open	0.37
Previous Close	0.39
Day's Range	0.33 - 0.37
52-Week Range	0.30 - 2.89
Analyst	n/a
Price Target	2 (506.06%)
Dividends	n/a
Ex-Dividend Date	n/a

About NXGL

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape des...

[Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

IPO Date Dec 22, 2021

Employees 19

Stock Exchange NasdaqCM

Ticker Symbol NXGL

Website https://nexgel.com

Full Company Profile

Financial Performance

In 2025, NEXGEL's revenue was 11.42M, an increase of 31.46% compared to the previous year's 8.69M. Earnings were -3M, a decrease of -8.56%.

Financial Statements

Analyst Forecast

According to 1 analyst ratings, the average rating for NXGL stock is "null". The 12-month stock price forecast is 2, which is upside of 506.06% from the latest price.

Stock Forecasts

Earnings Surprise

NEXGEL has released their quarterly earnings on Aug 17, 2026:

Revenue of $2.65M misses estimates by $0, with -5.56% YoY decline.

EPS of -0.52 misses estimates by -0.40, with -420.00% YoY decline.

Next Earnings Release

NEXGEL Inc. is scheduled to release its earnings on Nov 10, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

4 days ago · InvestorsHub

NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp

NEXGEL (NASDAQ:NXGL) reported second-quarter 2026 revenue of $3. 69 million and a net loss of $2.

3 months ago · Motley Fool

Nexgel (NXGL) Q1 2026 Earnings Transcript

On today's call, I would like to provide an overview of our first quarter 20 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we rece...